With over $113 million carryover funds for Cancer Moonshot activities in fiscal year (FY) 2025, funding was allocated into four budget mechanisms: research grants, R&D contracts, intramural research, and research management and support. This is shown in the chart below.
| Type of Mechanism | Mechanism | Number | Amount1 |
|---|---|---|---|
Research Project Grants (RPGs)
| Competing | 9 | $9,745,910 |
| Noncompeting | 42 | $56,812,979 | |
| Admin Supplements | 0 | $108,494 | |
| Subtotal, without SBIR | 0 | $0 | |
| SBIR/STTR Grants | 0 | $0 | |
| Subtotal, RPGs | 51 | $66,667383 | |
Centers
| Cancer Centers-P30s | 2 | $721,072 |
| P50s | 0 | $0 | |
| Cooperative Agreements-U54s/U41s | 0 | $0 | |
| Subtotal, Centers | 2 | $721,072 | |
Other Research
| Resource Grants-U24s/U2Cs | $40,841,100 | |
| Subtotal, Other Research | $40,841,100 | ||
| Subtotal, Research Grants | $108,229,566 | ||
| Intramural Research (IR) | IR Program | 0 | $2,644,408 |
| Research Management & Support (RMS) | RMS | 0 | $0 |
R&D Contracts
| R&D Contracts | $2,729,379 | |
| SBIR/STTR Contracts | $0 | ||
| Subtotal, R&D Contracts | $2,729,379 | ||
| Total | $113,603,353 | ||
| 1 Includes obligations and recoveries from fiscal years 2017, 2018, 2019, 2020, 2021, 2022, and 2023 carryover accounts. | |||